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We are submitting the revised version of the manuscript 2014-BJP-0951-RP entitled 
“FM19G11 reverses endothelial dysfunction in rat and human arteries through 
stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α 
activation” by El Assar, Royo, López-Hernández, Sánchez-Ferrer, Aceña, Rodríguez-
Mañas, Angulo, and myself to be considered for publication in the British Journal of 
Pharmacology. 
After having fulfilled most of the questions raised by the additional reviewer in the 
previous revision, we have now generated a point by point response to the new 
comments raised by the Editor and the reviewer and modified the manuscript 
accordingly (changes are highlighted). We think we have reasonably addressed the 
comments of the reviewer and the Editor and we hope that our work would be now 








José M. Sánchez-Puelles, PhD 
Molecular Pharmacology Group, Cellular and Molecular Medicine Dept., Centro de 
Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas. 
c/ Ramiro de Maeztu 9  
28040 Madrid, Spain. 
jm.spuelles@csic.es 
 
Page 1 of 50
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
Answers to Reviewer and Editor – Manuscript BJP-0951-RP.R1 
 
Editor's Comments to Author: 
The revised manuscript is now much improved but there are some important points 
raised by the final reviewer that still require attention. Addressing these matters may not 
require further experimentation if the authors a) decide change their stated conclusions 
to match the data and b) discuss the points raised with respect to the data presented in 
figure 5. However, doing so would change the conclusions of the paper somewhat and 
such changes may not be acceptable to the reviewer/editor. Of course, within the scope 
of a revision, it is possible to include additional data to address the points raised by the 
reviewer should the authors decide to do so. 
 
Although we were confident about the accuracy of the results presented in previous 
figure 5, in order to expedite acceptance, we have performed new determinations using 
immunofluorescence techniques to further support our conclusions. As expected, these 
new results presented in Figure 5 are confirmatory of our previous data and overcome 
the criticisms raised by the reviewer regarding previous Figure 5. Moreover, we have to 
note that our conclusions are not merely based in results shown in Figure 5; at this 
respect, we have provided Western blot and functional data with selective inhibitors 
(Figures 3 and 4) supporting that phosphorylation of Akt and eNOS is increased by 
FM19G11 and this effect is required for the improvement driven by this drug on 
endothelial vasodilation under endothelial dysfunction conditions.  
 
Please ensure that your drug/molecular target nomenclature (e.g. receptors, ion channels 
and so on) conforms to BJP's Concise Guide to Pharmacology, and add a comment to 
this effect in the Methods section, citing the source 'Concise Guide to 
PHARMACOLOGY citation', e.g. Alexander SPH, Benson HE, Faccenda E, Pawson 
AJ, Sharman JL, Spedding M, Peters JA and Harmar AJ, CGTP Collaborators. (2013) 
The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br 
J Pharmacol. 170: 1459-1581. 
 
We have ensured that nomenclature used for designating drugs and molecular targets 
conforms to BJP's Concise Guide to Pharmacology and we have introduced a sentence 
in this sense in the Methods section (page 14, lines 11-12). 
 
Reviewers' Comments to Author: 
 
Reviewer: 2 
Comments to the Author 
The authors have adequately addressed most of the points raised. 
However, it is still not clear that phosphorylation of eNOS and Akt were actually 
increased in FM19G11-treated aorta (Fig. 5).  In particular:-  
1. Fig. 5A: The nuclei of endothelial cells are too faint. Only two or three nuclei can be 
seen. Moreover,  phospho-Akt-positive nuclei cannot be discriminated from Akt-
positive ones. 
 
To further confirm our data, we have performed new determinations using 
immunofluorescence techniques to confirm the increase in phosphorylation of Akt and 
eNOS in aortae treated with FM19G11 either in vivo or ex vivo. These additional 
results support those originally provided by using immunohistochemistry approach 
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since almost complete absence of red fluorescence signal is obtained in untreated IRR 
aortae while a clear fluorescence is observed in FM19G11 treated aortae. Nuclei are 
clearly visible after counterstaining with DAPI in all samples. Due to inclusion of the 
new method for detection phospho-Akt and phospho-eNOS as shown in new Figure 5, 
we have modified accordingly Methods section (page 12, first paragraph) and 
corresponding figure legend. 
Moreover, we would like to note that the results shown in Figure 5 reinforce those we 
have provided by Western blot and functional data with selective inhibitors (Figures 3 
and 4) supporting that phosphorylation of Akt and eNOS is increased by FM19G11 in 
aorta from IRR and this effect is required for the improvement driven by this drug on 
endothelial vasodilation under endothelial dysfunction conditions. Taking all this data 




2. Fig. 5B: Although the authors indicated phospho-eNOS positive cells in the 
endothelial lining, there is no difference between phospho-eNOS positive and negative 
cells. If phospho-eNOS form is stained in the cytosol as in Fig5D, there seem to be no 
phospho-eNOS positive cells in Fig. 5B. 
 
New immunofluorescence assays show a clear line of positive endothelial cells only in 
FM19G11-treated aortae (Figure 5C and 5E). In fact, the difference with an untreated 
aorta from IRR (Figure 5A) is now more evident. 
 
3. Fig. 5E: The phospho-Akt staining was too faint to be discriminated as positive 
staining. 
 
In the same sense, we think that the new immunofluorescence assays shown in the new 
Figure 5 provide a better support to the conclusions than the previously shown figure. 
Although positive signal for p-Akt is less intense and localized than that of p-eNOS, 
there is no doubt that only after treatment with FM19G11 a clear fluorescence signal is 
appreciated in the aortae from IRR (Figure 5D and 5F). Although, more intense in 
endothelium, positive signal is also observed in smooth muscle cells. This is not 
unexpected since Akt is also expressed in smooth muscle cells. However, the increase in 
p-Akt translates into eNOS phosphorylation only in the endothelium where it is 
expressed (Figure 5C and 5E). 
 
4. Fig. 5G: why did the authors not present the quantification of phospho-Akt data in 
Fig. 5A, 5C, 5E? 
 
Following reviewer’s suggestion we also provide quantification of the percentage of 
endothelial cells positive for phospho-Akt (New Figure 5G). 
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BACKGROUND AND PURPOSE 
FM19G11 up-regulates mTOR/HIF-1α and PI3K/Akt pathways which are involved in 
endothelial function. We evaluated the effects of FM19G11 on defective endothelial 
vasodilatation in arteries from rats and humans and investigated the contributing 
mechanism. 
EXPERIMENTAL APPROACH: 
The effects of chronic in vivo administration of FM19G11 on aortic endothelial 
vasodilatation were evaluated together with ex vivo treatment in aortic and mesenteric 
arteries from control (CR) and insulin-resistant rats (IRR) as well as in human penile 
arteries (HPRA) and corpus cavernosum (HCC) from men with vasculogenic erectile 
dysfunction (ED) as a model of human endothelial dysfunction. Vascular expression of 
phosphorylated-endothelial NO synthase (p-eNOS), phosphorylated-Akt (p-Akt) and 
HIF-1α was determined by immunodetection while cGMP was monitored by ELISA. 
KEY RESULTS: 
Chronic administration of FM19G11 reversed the impairment of endothelial 
vasodilatation in IRR. Ex vivo treatment with FM19G11 also significantly improved 
endothelium-dependent vasodilatation in aorta and mesenteric arteries from IRR. These 
effects were accompanied by the recovery of p-eNOS and cGMP levels in IRR aorta 
and were prevented by either NOS or PI3K inhibition. p-Akt and p-eNOS contents were 
increased by FM19G11 in aortic endothelium of IRR. Improvement of endothelial 
vasodilatation by FM19G11 remained despite mTOR/HIF-1α inhibition. Finally, 
FM19G11 completely recovered endothelial vasodilatation in HPRA and HCC from ED 
patients. 
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CONCLUSIONS AND IMPLICATIONS: 
Stimulation of the PI3K/Akt/eNOS pathway with FM19G11 relieves impaired NO-
mediated endothelial vasodilatation in rat and human arteries independently of 
mTOR/HIF-1α activation. This pharmacological strategy could be beneficial for 
managing pathological conditions associated with endothelial dysfunction, such as 
erectile dysfunction.  
 
Keywords: endothelial dysfunction – insulin resistance – FM19G11 – endothelial nitric 
oxide synthase – phosphatidylinositol-3 kinase/Akt pathway – hypoxia inducible factor-
1 – human penile resistance arteries – erectile dysfunction 
Abbreviations 
ACh, acetylcholine; cGMP, cyclic guanosine monophosphate; CR, control rats; ED, 
erectile dysfunction; eNOS, endothelial NO synthase; HCC, human corpus cavernsoum; 
HIF-1α, hypoxia inducible factor-1α; HPRA, human penile resistance arteries; IRR, 
insulin-resistant rats; L-NAME, N
G
-nitro-L-arginine methyl ester; mTOR, mammalian 
target of rapamycin; p-eNOS, phosphorylated eNOS; p-Akt, phosphorylated Akt; PI3K, 
phosphatidylinositol-3 kinase; SNP, sodium nitroprusside. 
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Endothelial dysfunction is a key process in the pathogenesis of cardiovascular disease. 
It precedes the disease’s clinical manifestations and predicts future cardiovascular 
events (Green et al., 2011). Situations increasing cardiovascular disease risk, such as 
diabetes, hypertension and aging, are clearly associated with the presence of endothelial 
dysfunction. Therapeutic strategies targeted at preserving or recovering endothelial 
function are key to the prevention of cardiovascular disease. Nitric oxide (NO) 
participates in many functions of the endothelium and is a key mediator of endothelium-
dependent vasodilatation. In fact, the main risk factors for cardiovascular disease in 
humans share the characteristic of defective NO-mediated vasodilation (Paniagua et al., 
2001; Rodríguez-Mañas et al., 2009; Angulo et al., 2010). Thus, the recovery of NO 
signaling is an adequate strategy for overcoming endothelial dysfunction and preventing 
cardiovascular disease. 
The enzyme responsible for NO generation from the endothelium is endothelial NO 
synthase (eNOS). Its activity is triggered by a rise in intracellular calcium in response to 
various stimuli (acetylcholine, bradykinin, thrombin, shear stress, etc.) and is also 
regulated by post-translational mechanisms such as acylation, S-nitrosylation and 
phosphorylation (Michel and Vanhoutte, 2010). Among these, phosphatidyl-inositol-3-
kinase (PI3K)/Akt-dependent phosphorylation at Ser1177 is an important mechanism 
for enhancing NO synthesis by eNOS (Fisslthaler et al., 2000; Hisamoto et al., 2001; 
Symons et al., 2009). Furthermore, defective PI3K/Akt-dependent phosphorylation of 
eNOS contributes to the impairment of NO-mediated vasodilatation in pathological 
circumstances, including insulin resistance (Kobayashi et al., 2004; Li et al., 2010; 
Zhang et al., 2012). 
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Insulin resistance is a pathological situation defined by a defective action of insulin in 
target organs, compensated for by increased insulin secretion to maintain circulating 
glucose concentrations in normal range. In addition to predicting type-2 diabetes, 
insulin resistance represents an important risk for the development of cardiovascular 
disease (Hanley et al., 2002; Thacker et al., 2011; Reaven, 2012). This is probably 
related to the impact of insulin resistance on endothelial function, since impairment of 
endothelial vasodilatation has been demonstrated in different vascular areas in humans 
with this condition (Lteif et al., 2005; Suzuki et al., 2007; Fujii et al., 2008). In fact, 
induction of insulin resistance by feeding rats with high fructose results in defective 
endothelium-dependent relaxation in both macro- and micro-vessels (Shinozaki et al., 
1999; Katakam et al., 1999), providing a well-characterized model of endothelial 
dysfunction (Tran et al., 2009). 
Erectile dysfunction (ED) is an indicator of the existence of several peripheral 
vasculopathies (Goksu et al., 2014) and even predicts the presence of subclinical 
coronary artery disease (Jackson, 2013). In fact, ED is actually considered an indicator 
of systemic endothelial dysfunction and a sentinel symptom of silent generalized 
cardiovascular disease (Gandaglia et al., 2014). Vascular ED in men is indeed 
associated to a defective endothelium-dependent relaxation in key vascular structures 
involved in penile erection: penile arteries and corpus cavernsoum (Angulo et al., 
2010), representing an appropriate model of human endothelial dysfunction. 
Hypoxia transcription factor (HIF) has a prevalent position in the context of 
angiogenesis and pathological processes of cancer, inflammation and cardiovascular and 
neurodegenerative diseases (Majmundar et al., 2010; Royo et al., 2011). HIF-1α is 
thought to mediate cardio- and neuro-protection, in part by reprogramming cell 
metabolism. Therefore, it is conceivable that HIF-1α therapies could treat vascular and 
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metabolic diseases. Growing evidence supports a role for HIF-1α activity in the 
neoangiogenic response to tissue ischemia (Bosch-Marce et al., 2007). 
Therapies targeted to overcome the endothelial dysfunction associated with aging and 
other cardiovascular risk factors are definitely needed. FM19G11 is a novel compound 
that modulates transcriptional activity of HIF-α proteins under hypoxic conditions 
(Moreno-Manzano et al., 2010), while in normoxia it up-regulates protein expression of 
HIF-1α through rapid activation of the transcription factor, mammalian target of 
rapamycin (mTOR) (Rodriguez-Jimenez et al., 2010; 2012). Mechanistic analysis 
revealed that FM19G11 facilitates glucose availability and metabolism in ependymal 
stem cells by activating the PI3K/Akt pathway (Rodríguez-Jiménez et al., 2012).  
The aim of the present study was to evaluate the capacity of FM19G11 to reverse the 
impairment of endothelium-dependent vasodilatation in insulin-resistant rats, 
determining the involvement of PI3K/Akt/eNOS and mTOR/HIF-1α pathways. The 
validity of this pharmacological strategy to overcome endothelial dysfunction in a  
human model of endothelial dysfunction was evaluated in penile resistance arteries 
(HPRA) and corpus cavernosum (HCC) from patients with vasculogenic ED.   
Page 10 of 50
British Pharmacological Society





Animal model for insulin resistance 
Studies were performed in accordance with the Declaration of Helsinki and with the 
Guide for the Care and Use of Laboratory Animals, as adopted and promulgated by 
National Institutes of Health, and were approved by the local Ethics Committee for 
Animal Experimentation of the Hospital Universitario de Getafe. All studies involving 
animals are reported in accordance with the ARRIVE guidelines for reporting 
experiments involving animals (McGrath et al., 2010). A total number of 90 male 
Wistar rats (Harlan, Barcelona, Spain) under 12 h light/dark cycles with free access to 
food and water were used. Fructose-fed rats were used as a model of insulin resistance. 
This is a widely characterized model (Tran et al., 2009) that has been shown to be 
associated with impairment of endothelial vasodilatation (Shinozaki et al., 1999). Four 
to five week-old rats were fed with fructose (20%) in drinking water for 8 weeks. Age-
matched rats maintained in the same conditions but not receiving fructose in drinking 
water were used as controls (non-insulin-resistant). Insulin-resistant rats continuing on 
high-fructose diet were treated intraperitoneally (1 ml·kg
-1





) or vehicle (25% dimethylsulfoxide) for 7 days. This duration of treatment was 
chosen based on previously reported functional benefits in spinal cord injury 
regeneration in rats after one week of FM19G11 administration (Rodríguez-Jiménez et 
al. 2012).  Then, rats were killed and aortae and mesenteric arteries were obtained for 
vascular reactivity experiments. Rats were fasted overnight before death and serum was 
obtained for determination of glucose and insulin concentrations. 
Serum glucose and insulin determinations 
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Circulating levels of insulin were determined in rat serum by ELISA, following the 
manufacturer’s instructions (Mercodia AB, Sweden, cat. # 10-1250-01). Serum glucose 
concentrations were determined by a colorimetric commercial kit (Biolabo SA, Maizy, 
France, cat. # LP80209). All samples were assessed in duplicate. Homeostasis Model 
Assessment of Insulin Resistance (HOMA-IR) index was calculated as described by 
Mathews et al. (1985) and normalized to the value obtained in control rats. 
Relaxation of aortic segments 
Rats were anesthetized with ketamine (50 mg·kg
-1
) and diazepam (4 mg·kg
-1
) and killed 
by bleeding. The thoracic aorta was carefully excised, cleaned of surrounding fat and 
connective tissue and placed in a Petri dish with Krebs-Henseleit solution (KHS) at 4ºC. 
Composition of KHS was (in mM): NaCl 119, KCl 4.6, CaCl2 1.5, MgCl2 1.2, NaHCO3 
24.9, glucose 11, KH2PO4 1.2 and EDTA 0.027. Aortae were cut into 4 to 5 mm-long 
cylindrical segments. For circular isometric tension recording, each vascular cylinder 
was set up in an organ bath containing KHS at 37ºC continuously bubbled with 95% O2/ 
5% CO2 mixture, which gave a pH of 7.4, according to the method described elsewhere 
(Angulo et al., 1996). Tension was continuously recorded in a data acquisition system 
(MP100A BIOPAC System, Santa Barbara, CA, USA). Aortic segments were 
contracted with norepinephrine (NE, 10-30 nM) and, when a stable plateau was reached, 
increasing concentrations of acetylcholine (ACh, 0.01 to 10 µM), insulin (0.01 nM to 1 
µM) or sodium nitroprusside (SNP; 1 nM to 10 µM) were added and vasodilatory 
responses were determined. For evaluation of the acute effects of experimental 
treatments on endothelial vasodilatation, treatments were randomly assigned to different 
segments from the same animal and the experiments were systematically performed in 
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parallel for each series of experiments. Each vascular segment received only one of the 
treatments. 
Determination of Cyclic Guanosine Monophosphate Content in Rat Aorta  
Rat aortic segments treated for 30 min with vehicle, FM19G11 (1 µM), L-NAME (100 
µM) or FM19G11 plus L-NAME, were exposed for 5 min to 10 µM ACh, immediately 
frozen in liquid nitrogen and then stored at -80ºC till extraction for cyclic nucleotide 
assay. Cyclic nucleotides were extracted by homogenization in 6% trichloroacetic acid, 
followed by ether (H2O-saturated) extraction and lyophilization. cGMP concentration 
was determined by enzyme-linked immunosorbent assay, using a kit from Cayman 
Chemical Company (Ann Arbor, MI, USA, cat. # 581021) (Angulo et al., 2010). 
Vascular reactivity of rat mesenteric arteries 
Second to third order branches of mesenteric arterial tree (lumen diameter 200-400 µm) 
were obtained from omentum specimens and dissected by carefully removing the 
adhering fat tissue. Arterial ring segments (2 mm long) were subsequently mounted on 
microvascular wire myographs (J.P. Trading, Aarhus, Denmark) for circular isometric 
tension recordings, as described elsewhere (Rodríguez-Mañas et al., 2003). The vessels 
were allowed to equilibrate for 30 min in KHS continuously bubbled with 95% O2/5% 
CO2 mixture to maintain a pH of 7.4. The passive tension and internal circumference of 
vascular segments when relaxed in situ under a transmural pressure of 100 mmHg 
(L100), were determined. The arteries were then set to an internal circumference 
equivalent to 90% of L100, at which the force development is close to maximal 
(Mulvany and Halpern, 1977). Preparations were then exposed to 125 mM K
+
 (KKHS, 
equimolar substitution of NaCl for KCl in PSS) and the contractile response was 
measured. After a stabilization period, rat arteries were contracted with 1-3 µM NE 
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(80% of KKHS-induced contraction, approximately) and relaxation responses were 
evaluated by cumulative additions of ACh (1 nM to 10 µM) to the chambers. 
Experiments were run in parallel. Concentration-response curves to the agents in arterial 
segments from the same animal that previously received only vehicle (0.01% DMSO) 
were considered as controls for the evaluation of the effects of the different treatments. 
Western Blot analysis 
Total protein extracts were obtained by homogenization of aortic tissue with a MagNA 
Laser electric homogenizer using T-PER extraction reagent (Pierce Biotechnology, Inc., 
Rockford, IL) according to the manufacturer’s recommendations, with the addition of 
1x Protease Inhibitor Cocktail and 1x Phosphatase Inhibitor Cocktail (Roche 
Diagnostics, IN). Equal amounts of protein extracts (20 µg) were loaded onto a 10% 
SDS-polyacrylamide gel and resolved by standard SDS-PAGE. Proteins were 
electrophoretically transferred onto PVDF membranes. Membranes were blocked with 
5% skimmed milk in phosphate-buffered saline containing 0.1% Tween 20 for 60 min 
and tested overnight with specific antibodies at 1:500 dilution against eNOS, phospho-
eNOS (Ser1177) (Abcam, Cambridge, UK, cat # ab66127 and ab75639, respectively), 
HIF-1α, HIF-2α (Novus, Littleton, CO, USA, cat. # NB100-105 and NB-100-122, 
respectively), Akt, phospho-Akt (Ser473) (Cell Signaling, Danvers, MA, cat # 2920S 
and 4060S, respectively) and at 1:5,000 dilution against β-actin (Sigma, St. Louis, MO, 
cat. # A1978), which was used as loading control. Subsequently, membranes were 
incubated with rabbit anti-mouse or goat anti-rabbit horseradish peroxidase-conjugated 
secondary antibody (1:5,000) (Sigma). Blots were visualized by the ECL detection 
system (Amersham Biosciences, Piscataway, NJ). Results were quantified by 
densitometry, using QuantityOne/Chemi-Doc Software (Bio-Rad, Barcelona, Spain). 
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Rat aortic segments were fixed in 4% paraformaldehyde and included in paraffin 
blocks. Antigen retrieval was achieved by heating deparaffinized tissue sections (5 µm) 
in citrate buffer (pH 6). Following blockade with 5% bovine serum albumin (BSA) plus 
0.3% Triton X-100 in phosphate-buffered saline (PBS) for 1 hour at 37ºC, sections were 
incubated with antibodies against phospho-Akt (1:100 dilution) or against phospho-
eNOS (1:200 dilution) overnight at 4 ºC. After washout in PBS plus 0.3% Triton X-100, 
the sections were incubated with a secondary Alexa Fluor 546-conjugated goat anti-
rabbit antibody (dilution 1:250; Life Technologies, Alcobendas, Spain) and with 
diamidino-2-phenylindole (DAPI, Life Technologies) to counterstain nuclei for 1 hour 
at room temperature. Sections were mounted and viewed by fluorescence microscopy 
(Olympus BX51, Japan). Controls without primary antibodies showed no unspecific 
reactivity (data not shown).  Images from each aortic specimen were captured and the 
total number of endothelial cells as well as the number of those positive for p-eNOS and 
p-Akt were determined and the percentages of endothelial cells positive for p-eNOS and 
p-Akt were calculated.  
Human tissues 
Human penile tissue biopsies were obtained from 9 men with erectile dysfunction (ED) 
who gave informed consent at the time of penile prosthesis insertion. The patients had 
an average age of 59.0±2.3 years (range 46-71). Five were hypertensive, three had 
dyslipidemia, two had type 2 diabetes, two had manifested cardiovascular disease, one 
suffered from atrial fibrillation, one was obese and two had a smoking habit. The 
etiology of ED was considered as vascular in all patients. Healthy cavernosal specimens 
were obtained from 10 organ donors (without history of ED or vascular risk factors) at 
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the time of organ extraction for transplantation (average age 48.7±5.3 years, range 23-
62). The study was approved by the Ethics Committee of Hospital Santo Antonio, Porto 
(081/10(059-DEFI/077-CES)), where the samples were collected. Tissues were 
maintained at 4º to 6ºC in M-400 solution (composition in mM: mannitol, 230; KH2PO4, 
15; K2HPO4·3H2O, 43; KCl, 15; NaHCO3, 10) until used, which was between 16 and 24 
hours after extraction (Angulo et al., 2002; Angulo et al., 2010; González-Corrochano 
et al., 2013). 
Experiments with human penile resistance arteries 
Small penile arteries — helicine arteries (lumen diameter 150 µm to 400 µm), which are 
the terminal branches of deep penile arteries — were dissected by carefully removing 
the adhering trabecular tissue. Then arterial ring segments (2-mm long) were mounted 
on microvascular wire myographs for circular isometric tension recordings, as described 
elsewhere (González-Corrochano et al., 2013). The arteries were then set to an internal 
circumference equivalent to 90% in the same way as described above for rat mesenteric 
arteries. The preparations were then exposed to 125 mM K
+
 (KKHS) and the contractile 
response was measured. The arteries were contracted with 1 to 3 µM of NE (80% of 
KKHS-induced contraction, approximately), and relaxation response was evaluated by 
cumulative additions of ACh to the chambers. After extensive washout and 
equilibration period, FM19G11 (1 µM) or vehicle (0.01% DMSO) were added 30 min 
before contraction with NE for re-evaluating ACh-induced responses. 
Experiments with human corpus cavernosum tissue 
Strips of corpus cavernosum tissue (3 x 3 x 7 mm) obtained from human penile tissue 
specimens were immersed in 8 ml organ chambers containing PSS, maintained at 37ºC 
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and aerated with 5% CO2/95% O2, pH 7.4.  Each tissue strip was incrementally 
stretched to optimal isometric tension, as determined by maximal contractile response to 
1 µM phenylephrine (PE). The preparations were then exposed to KKHS and the 
contractile response was measured.  After an equilibration period, tissues were 
contracted with 1 - 3 µM PE (80% of KKHS induced contraction) and relaxation 
responses were evaluated by cumulative additions of ACh to the chambers. After 
extensive washout and equilibration period, FM19G11 (1 µM) or vehicle (0.01% 
DMSO) were added 30 min before contraction with PE for re-evaluating ACh-induced 
responses. 
Drugs and Materials 
Nomenclature used for designating drugs and molecular targets conforms to BJP's 
Concise Guide to Pharmacology (Alexander et al. 2013). Norepinephrine (arterenol), 
phenylephrine, acetylcholine, sodium nitroprusside, N
G
-nitro-L-arginine methyl ester 
(L-NAME), wortmannin and rapamycin were obtained from Sigma Chemical Co. (St. 
Louis, MO). Human insulin (Humulin
®
) was obtained from Lilly España (Alcobendas, 
Madrid, Spain). FM19G11 (3-[(2,4-dinitrobenzoyl)amino]-benzoic acid 2-(4-
methylphenyl)-2-oxoethyl ester) was synthesized at Departamento de Química 
Orgánica, Centro de Investigación Príncipe Felipe, Valencia, Spain. For in vitro 
experiments, all drugs were dissolved in deionized water, except for FM19G11, 
wortmannin and rapamycin which were dissolved at 10 mM concentration in 
dimethylsulfoxide (DMSO). The subsequent dilutions were made in deionized water. 
Final DMSO concentration was 0.01% or lower. 
Statistical analysis 
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Two-factors analysis of variance (ANOVA) was applied to analyse the effects of the 
treatments on the complete concentration-response curves. Expression data and cGMP 
values were compared by one-factor ANOVA followed by Student-Newmann-Keuls 
test. pD2 was defined as the –log M of the concentration required to obtain 50% 
relaxation. Emax is the maximal relaxation response expressed as percentage. pD2 and 
Emax data given in the text were compared by Student t-test except those involving more 
than two groups where one-factor ANOVA followed by Student-Newmann-Keuls test 
was used. 
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Systemic administration of FM19G11 recovers endothelium-dependent vasodilatation 
in insulin-resistant rats. 
Fructose-fed rats developed insulin resistance, as confirmed by the significant increase 
in the HOMA-IR score (3.15±0.44-fold increase; p < 0.001). The increase in HOMA-IR 





) (p < 0.05 vs. untreated fructose-fed rats). Aortic segments 
from vehicle-treated insulin-resistant rats (IRR) displayed significantly diminished 
vasodilatation in response to ACh (10 nM to 10 µM) than segments from control rats 
(CR). Administration of FM19G11 completely reversed the impairment of endothelial 
vasodilatation, since ACh-induced responses in aortic segments from IRR treated with 
FM19G11 were not significantly different from those obtained in aortae from control 
rats (Figure 1A). Vasodilatation caused by insulin (0.01 nM to 1 µM) in aorta was also 
blunted in IRR. Treatment of IRR with FM19G11 resulted in the recovery of insulin-
induced dilations to the level of control rats (Figure 1B). Endothelium-independent 
vasodilatations caused by the nitric oxide donor, sodium nitroprusside (SNP; 1 nM to 10 
µM), were not altered by the presence of insulin resistance and were not modified by the 
treatment with FM19G11 (pD2 8.22±0.04, 8.31±0.13 and 8.42±0.04 for CR, IRR and 
IRR+FM19G11; n.s.). 
 
Acute preincubation of arteries from IRR with FM19G11 improves endothelium-
dependent vasodilatation 
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Preincubation for 30 minutes with FM19G11 (1 µM) did not significantly modify 
endothelium-dependent relaxation of aortic segments from CR (Figure 2B). At 0.3 µM 
concentration, FM19G11 induced a modest but significant increase in ACh-induced 
vasodilatation in IRR aorta (Figure 2C), but, when FM19G11 concentration was 
increased to 1 µM, a marked improvement in endothelial vasodilatation in IRR aorta 
was seen (Figure 2A and 2D). At this concentration, FM19G11 also enhanced 
vasodilatation driven by insulin in IRR aorta (Emax 54.1±4.0% vs 70.7±5.3%, p < 0.05). 
This improvement of endothelium-dependent vasodilatation by FM19G11 (1 µM) was 
confirmed in small mesenteric arteries from IRR rats (Figure 2E). Similar to that 
observed in aorta, ACh-induced responses were not significantly modified by FM19G11 
(1 µM) in mesenteric arteries from CR (pD2 7.48±0.10 vs 7.73±0.25; n.s.). 
Enhancement of endothelial vasodilation by FM19G11 is unlikely to be due to 
destabilization of adrenergic tone. This is supported by the fact that the treatment with 
FM19G11 did not influence the NE-induced tone in aorta from IRR when vehicle was 
administered instead of ACh whereas potentiation of ACh-induced vasodilation is 
clearly observed (Figure 2A). In addition, contraction data provided in figure legends 
demonstrate the lack of potential interference of contractile tone on the effects exerted 
by FM19G11 on vascular relaxation. 
 
Enhancing effects of FM19G11 on endothelial function are mediated by the 
NO/cGMP pathway 
ACh-induced relaxation of aortic segments in IRR is mainly mediated by NO, since 
inhibition of NOS with N
G
-nitro-L-arginine methyl ester (L-NAME; 100 µM) almost 
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abolished endothelium-dependent vasodilatation. When the NOS inhibitor was present, 
FM19G11 (1 µM) failed to exert its enhancing effect on ACh-induced responses (Figure 
3A). After exposure of aortic tissue to ACh, the intracellular content of the second 
messenger of NO, cyclic guanosine monophospate (cGMP), was reduced in IRR. In 
ACh-stimulated aortic tissue from IRR, the treatment with FM19G11 significantly 
increased the cGMP content, while a non-significant increment was observed in aortic 
tissue from CR (Figure 3B). The requirement of NO synthesis for these effects on 
cGMP accumulation was confirmed by the fact that L-NAME reduced cGMP level in 
ACh-stimulated aortic tissue and prevented the increase in cGMP content driven by 
FM19G11 (Figure 3B). Protein amounts in the phosphorylated form of eNOS at 
Ser1177 (p-eNOS) relative to total eNOS content were significantly reduced in IRR 
aortae. Treatment with FM19G11 (1 µM) for 30 minutes caused a significant increase in 
the aortic p-eNOS/eNOS ratio in these rats (Figure 3C). FM19G11 (1 µM) did not 
significantly modify aortic content of total eNOS in CR or IRR (eNOS/ß-actin ratios 
were 0.796±0.118 and 0.805±0.107 for vehicle- and FM19G11-treated aortae from CR, 
and 0.756±0.135 and 0.732±0.110 for vehicle- and FM19G11-treated aortae from IRR). 
 
Improvement of endothelial vasodilatation in IRR aorta by FM19G11 involves 
activation of the PI3K/Akt/eNOS pathway. 
Inhibition of phosphatidyl inositol-3 kinase (PI3K) by wortmannin (500 nM) did not 
modify ACh-induced vasodilatation in IRR aorta significantly, but completely 
prevented the enhancing effects induced by FM19G11 (1 µM) on these responses 
(Figure 4A). This suggests the involvement of the PI3K/Akt pathway in FM19G11-
induced improvement in endothelial vasodilatation in IRR. In this sense, although Akt 
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expression was not significantly modified by FM19G11 (1 µM) (0.897±0.170 and 
0.863±0.152 for vehicle- and FM19G11-treated aortae from IRR), increased 
phosphorylation of Akt was observed after 30 min incubation with FM19G11 (1 µM) in 
IRR aortae, an effect that was prevented by co-treatment with wortmannin (500 nM) 
(Figure 4B). Furthermore, increased amounts of the phosphorylated forms of Akt and 
eNOS were immunodetected in aortic endothelium from IRR after either chronic (7 




; i.p. and 1 µM, 
respectively) (Figure 5). Quantification of endothelial cells (ECs) positive for p-Akt in 
aortae from IRR yielded a significant increase in the percentage of ECs expressing p-
Akt after acute or chronic exposure to FM19G11 (Figure 5G). Consistently, the 
percentage of ECs positive for p-eNOS increased in aorta from IRR after treatment with 
FM19G11 (Figure 5H). 
 
Improvement of endothelial vasodilatation caused by FM19G11 is not dependent on 
upregulation of HIF-1α. 
Consistent with the previously reported ability of FM19G11 to upregulate mammalian 
target of rapamycin (mTOR)/HIF-1α signaling under normoxic conditions in different 
cell types (Rodríguez-Jiménez et al., 2012), treatment for 30 min with this compound 
resulted in increased aortic expression of HIF-1α protein in both CR and IRR (Figure 
6A). However, this upregulation of HIF-1α driven by FM19G11 seems not to be 
responsible for the improving effects of this molecule on endothelial vasodilatation in 
IRR, since the inhibition of mTOR with rapamycin (20 µM) did not prevent the 
improvement induced by FM19G11 on ACh-induced vasodilatation in IRR aorta 
(Figure 6B). Western blot example in figure 6C clearly shows that mTOR inhibition 
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with rapamycin (20 µM) prevented HIF-1α upregulation induced by FM19G11 in aorta 
from IRR while it did not preclude FM19G11-induced enhancement of Akt 
phosphorylation. On the other hand, HIF-2α/ß-actin ratio was not significantly modified 
by the treatment with FM19G11 (1 µM) in aortae from CR (0.877±0.064 vs. 
0.703±0.187 for vehicle and FM19G11, respectively, n=3) or IRR (0.706±0.095 vs. 
0.739±0.175 for vehicle and FM19G11, respectively, n=3). 
FM19G11 reverses impairment of endothelial vasodilation in human penile arteries 
and corpus cavernosum from patients with vascular erectile dysfunction 
Endothelium-dependent vasodilatation elicited by ACh (1 nM to 10 µM) in HPRA from 
patients with vascular erectile dysfunction was not modified after treatment with the 
vehicle (0.01% DMSO) (pD2 5.93±0.34 vs. 6.08±0.32; n.s.). Impaired endothelial 
vasodilatation was observed in HPRA from ED patients when compared to HPRA from 
No ED subjects but this impairment was reversed by treating arterial segments with 
FM19G11 (1 µM), as can be clearly observed in tracings in Figure 7A. Measurement of 
the results showed a significant potentiation of ACh-induced vasodilation of HPRA by 
FM19G11 (Figure 7B). This resulted in the recovery of endothelial vasodilatation in 
HPRA from patients with vasculogenic ED, since endothelial vasodilatory responses 
were comparable to those obtained in arteries from healthy penile tissues. Similar 
results were obtained when the effects of FM19G11 on endothelium-dependent 
relaxation of human corpus cavernosum (HCC) were evaluated. FM19G11 (1 µM) 
improved relaxations induced by ACh (1 nM to 10 µM) in HCC from patients with 
vascular ED to a relaxation response similar to that obtained in HCC from patients 
without ED (Figure 7C). 
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Present results show that continued systemic administration of FM19G11 reverses the 
impairment of endothelium-dependent vasodilatation caused by insulin resistance in rat 
aorta. In fact, short-term incubation with FM19G11 improved endothelial vasodilatation 
in aorta and mesenteric arteries of insulin-resistant rats. FM19G11 exerted its protective 
effect through the PI3K/Akt/eNOS/cGMP pathway, since first, it was abolished by NO 
synthesis inhibition, second, it was prevented by PI3K inhibition and, finally, it was 
associated with an increment in the phosphorylated forms of Akt and eNOS, and a 
cGMP increase in aortic tissue from IR rats. Although FM19G11-induced actions were 
paralleled by an increase in HIF-1α protein content in aortic tissue, HIF-1α did not 
significantly contribute to the positive effects of FM19G11 on endothelial 
vasodilatation. The ability of FM19G11 to recover defective endothelium-dependent 
vasodilatation was confirmed in human penile arteries and corpus cavernosum from 
patients with endothelial dysfunction. 
Aging and metabolic disorders lead to abnormal endothelial function that implies 
vascular damage and, ultimately, cardiovascular disease. Although there are portfolios 
of safe drugs to treat metabolic diseases, few of them, if any, are oriented to the 
endothelial function, with a view to avoiding the long-term undesired side-effects of 
metabolic disorders, such as cardiovascular disease. Therefore, there is an urgent 
clinical need to identify novel mechanisms of action focusing on impeding endothelium 
deterioration. The rationale for evaluating the effects of FM19G11 on endothelial 
vasodilatation is based on evidence demonstrating its ability to activate PI3K/Akt and 
mTOR/HIF-1α in ependymal stem cells under normoxic conditions (Rodríguez-Jiménez 
et al., 2012). The PI3K/Akt pathway regulates the phosphorylation of eNOS at Ser1177, 
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which results in increased synthesis of NO by this enzyme and enhances vasodilatatory 
response, a process that might be compromised in pathological situations associated 
with endothelial dysfunction (Kobayashi et al., 2004; Li et al., 2010; Zhang et al., 
2012).  
Results confirm the hypothesis that FM19G11 exerts positive effects on endothelial 
vasodilatation when endothelial dysfunction is present, as demonstrated by the data 
obtained after administration of the drug in a well-accepted rat insulin-resistance model 
with endothelial dysfunction. The impairment of endothelial vasodilatation caused by 
insulin resistance in rats was reversed by chronic in vivo treatment with FM19G11. This 
beneficial in vivo effect on vasodilatation was also produced by short-term 
preincubation of the arteries ex vivo, suggesting that FM19G11 acts on vascular tissue. 
This effect was not limited to a specific vascular area, since it occurred in both large 
(aorta) and resistance (mesenteric) arteries, which differ in blood flow regulatory 
functions. The improvement of vasodilatation by FM19G11 was mediated by the NO 
pathway in IRR aorta, as this effect was prevented by the NOS inhibitor, L-NAME. NO 
generation by endothelium stimulates soluble guanylyl cyclase in vascular smooth 
muscle, promoting cGMP formation that triggers intracellular processes leading to 
smooth muscle relaxation and vasodilatation (Moro et al., 1996). Accumulation of 
cGMP in aortic tissue in response to endothelial stimulation was reduced in IRR aorta, 
but was recovered by exposure to FM19G11, demonstrating that this compound 
strengthens the NO/cGMP pathway. This is probably accomplished by the observed 
increase in eNOS phosphorylation driven by FM19G11 in aortic tissue from IRR. In 
fact, FM19G11 treatment recovered the amount of phospho-eNOS in IRR aorta, which 
was lower than in CR. Therefore, phosphorylation at Ser1177 confers increased activity 
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on eNOS, leading to greater NO synthesis and enhanced vasodilatation. Thus, 
functional recovery of vasodilatation in IRR by systemic administration of FM19G11 
could be triggered at the molecular level by adequate phosphorylation of eNOS. This 
result clearly suggests that pharmacological interventions leading to eNOS activation 
could be a reasonable way of overcoming endothelial dysfunction and thus preventing 
vascular damage. 
Overactivation of PI3K/Akt is likely the mechanism leading to phospho-eNOS increase 
after treatment with FM19G11, since inhibition of PI3K with wortmannin completely 
prevented the positive effects of FM19G11 on aortic vasodilation in IRR. PI3K/Akt 
involvement in FM19G11-induced effects is further supported by the results obtained 
with an additional PI3K inhibitor. LY294002 does not inhibit myosin light chain kinase 
(MLCK) at concentration used (Yano et al. 1995), but, similarly to wortmannin, it 
prevented the improvement of vasodilatation exerted by FM19G11 in aorta from IRR. 
In confirmation of these results, immunodetermination experiments done after exposure 
to FM19G11 showed increased phosphorylation of Akt in aortic tissue from IRR, which 
was prevented by inhibition of PI3K. Although immunodetection of phosphorylated 
proteins, phospho-eNOS and phospho-Akt, in aortic tissue homogenates do not allow 
for determining if endothelium or smooth muscle, which is the major component of 
aortic tissue, are the source of phosphorylated proteins, immunolocalization assays 
show that both chronic and acute treatments with FM19G11 increased phospho-eNOS 
and phospho-Akt in aortic endothelium from IRR. This evidence strongly suggests that 
FM19G11 activates the PI3K/Akt pathway in endothelial cells, promoting increased 
phosphorylation and therefore activation of eNOS, the latter increasing NO availability 
and producing larger quantities of cGMP that cause enhanced vasodilatation. This 
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concept is further supported by the ability of in vivo as well as in vitro treatment with 
FM19G11 to improve insulin-mediated vasodilatation, since this response has been 
firmly postulated as produced by eNOS phosphorylation via the PI3K/Akt pathway 
(Montagnani et al., 2002; Kobayashi et al., 2005; Gentile et al., 2008). It is worth 
mentioning here that previous publications showed that FM19G11 also activates the 
serine/threonine-protein kinase ATR, a protein structurally related to PI3K (Rodríguez-
Jiménez et al., 2010, 2012) 
FM19G11 has been described as enhancing glucose metabolism in ependymal stem 
cells (Rodríguez-Jiménez et al., 2012). This is compatible with the lowering effect 
exerted by FM19G11 on HOMA-IR in fructose-fed rats. In fact, since insulin action 
involves activation of PI3K/Akt signalling, the reduction in HOMA-IR would be 
consistent with the ability by FM19G11 to enhance this pathway.  The reduction in 
HOMA-IR is an important feature confers potential relevance to FM19G11 for 
increasing insulin sensitivity. However, although improved glucose disposal at the 
systemic level could contribute to the beneficial effects of chronic FM19G11 on 
endothelial function, it cannot explain the improving effect exerted by acute FM19G11, 
which is probably mediated by acting on endothelial cells. 
It is relevant to note that FM19G11, in addition to activating the PI3K/Akt pathway, has 
also been reported to activate the mTOR/HIF-1α pathway and promote HIF-1α
 
upregulation in stem cells under normoxic conditions (Rodríguez-Jiménez et al., 2010; 
2012). This was also the case in rat vascular tissue, since FM19G11 induced a 
significant increase in HIF-1α protein content in aorta from both CR and IRR. Although 
upregulation of HIF-1α reverses the inability of aged mice to recover perfusion and 
motor function in ischemic hindlimbs (Bosch-Marce et al., 2007; Di et al., 2013), it 
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does restore the blunted inotropic response of hearts from old rats (Tan et al., 2010) and 
contributes to cardiac repair by cell therapy (Cerrada et al., 2013), HIF-1α elevation 
triggered by FM19G11 does not seem to be related to its capacity to overcome 
endothelial dysfunction in IRR. This is demonstrated by the fact that inhibition of 
mTOR with rapamycin prevented the increase in HIF-1α expression induced by 
FM19G11 but without affecting the increment in Akt phosphorylation and, 
consequently, did not impede the improvement of endothelial vasodilation driven by 
FM19G11 in IRR aorta. mTOR-mediated up-regulation of HIF-1α may be a 
consequence of PI3K/Akt pathway activation in normoxia (Agani and Jiang, 2013). 
Whether this is so for FM19G11 or it is produced by an independent mechanism is 
irrelevant to the improvement of endothelial vasodilatation by FM19G11, since the 
switching off of HIF-1α expression did not alter such an effect. Although it has been 
suggested that HIF-2α is involved in endothelial homeostasis (Ahmad et al., 2013) and 
it was reported that FM19G11 inhibited HIF-2α expression under hypoxic conditions in 
cancer cells and embryonic stem cells (Moreno-Manzano et al., 2010), FM19G11 failed 
to significantly modify HIF-2α content in aortic tissue in our oxygen abundance 
conditions. HIF-2α expression is controlled by mTOR complex 2 (mTORC2) rather 
than mTORC1 (Toschi et al., 2008). It is assumed that mTORC2 is less sensitive to 
rapamycin than mTORC1 but the high concentration of rapamycin (20 µM) used in our 
study has been demonstrated to block mTORC2 signalling in vascular tissue (Gao et al. 
2011). Thus, the lack of inhibition by rapamycin on FM19G11-induced improvement of 
endothelial vasodilatation in IRR suggests that the recovery of endothelial function by 
FM19G11 is not contributed by any interference of FM19G11 with either HIF-1α or 
HIF-2α expression. 
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Endothelial dysfunction associated to the presence of cardiovascular risk factors is 
assumed to play a key role in ED of vascular aetiology (Gratzke et al., 2010). In fact, 
human penile resistance arteries (HPRA) and corpus cavernosum (HCC) from patients 
with ED show an impaired endothelial vasodilatation, which is associated with a 
defective NO/cGMP pathway in penile tissue (Angulo et al., 2010). The presence of a 
broad spectrum of cardiovascular risk factors, including elevated age, could contribute 
to endothelial dysfunction in our ED patients. In this context, treatment with FM19G11 
improved endothelium-dependent vasodilation in HPRA and HCC from patients with 
vascular ED, which may reflect the presence of systemic endothelial dysfunction 
(Gandaglia et al., 2014). Thus, consistent with the results obtained in rats, FM19G11 is 
able to enhance endothelial vasodilatation in human vasculature characterized for 
having endothelial dysfunction and defective NO pathway. This demonstrates that the 
mechanism triggered by FM19G11 is efficacious in improving endothelial function in 
rat and human vasculature. It is not limited to the reversion of endothelial impairment 
specifically caused by insulin resistance, but seems to improve vasodilatation in a 
broader spectrum of pathological conditions associated with endothelial dysfunction.   
In conclusion, FM19G11 improves endothelial dysfunction due to an effect on the NO-
mediated responses by a mechanism linked to the activation of the PI3K/Akt pathway 
but not to mTOR activation/HIF-1α expression. This effect is not restricted to a unique 
pathological mechanism of endothelial dysfunction and seems to be present in both 
animal models of disease and human conditions. 
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Figure 1. Recovery of endothelium-dependent vasodilatation in aorta from insulin-





; i.p.) for 7 days on endothelium-dependent vasodilatation elicited by 
acetylcholine (ACh; 10 nM to 10 µM) (A) or insulin (0.01 nM to 1 µM) (B) in aorta 
from insulin-resistant rats (IRR). Vasodilatations obtained in aorta from control rats 
(CR; non-insulin-resistant) are shown for comparison. Data are expressed as 
mean±SEM of the contraction induced by norepinephrine (NE; 1.80±0.13 g, 1.88±0.16 




 in A, n.s.; 





 in B, n.s.). n indicates the number of vascular segments used for determinations 
that were obtained from 12 CR, 16 IRR and 6 IRR treated with FM19G11. *** indicates 
p < 0.001 versus CR and ††† p < 0.001 versus IRR by a two-factor ANOVA test. 
 
Figure 2. Acute treatment with FM19G11 improves endothelium-dependent 
vasodilatation in arteries from insulin-resistant rats. Panel A displays representative 
tracings showing the improvement of endothelium-dependent vasodilatation elicited by 
acetylcholine (ACh; 10 nM to 10 µM) by FM19G11 (1 µM) (left traces) and the lack of 
contractile tone destabilization by the same treatment (right traces) in aortic segments 
from insulin-resistant rats (IRR). Other panels show the effects of preincubation with 
FM19G11 (0.3 or 1 µM) on vasodilatation elicited by ACh in aorta from control rats 
(CR) (B), in aorta from IRR (C, D) or in mesenteric arteries from IRR (E). Data are 
expressed as mean±SEM of the contraction induced by norepinephrine (NE; 1.99±0.08 
g vs. 1.96±0.10 g; 1.92±0.12 g vs. 1.86±0.14 g; 1.77±0.08 g vs. 1.82±0.07 g; and  
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9.28±0.71 mN vs. 8.48±0.82 mN, control vs. FM19G11 for B, C, D and E, respectively; 
n.s. for all comparisons). n indicates the number of vascular segments used for 
determinations obtained from, at least, three different animals. *** indicates p < 0.001 
versus control by a two-factors ANOVA test. 
 
Figure 3. Involvement of the NO/cGMP pathway in FM19G11-induced 
improvement of endothelial vasodilatation in insulin-resistant rats. Panel A shows 
the influence of the NO synthase (NOS) inhibitor, N
G
-nitro-L-arginine methyl ester (L-
NAME; 100 µM), on the effects of FM19G11 (1 µM) on endothelium-dependent 
vasodilatation elicited by acetylcholine (ACh; 10 nM to 10 µM) in aorta from insulin-
resistant rats (IRR). Data are expressed as mean±SEM of the contraction induced by 
norepinephrine (NE; 2.10±0.33 g, 2.45±0.32 g, 2.08±0.23 g and 2.44±0.32 g for IRR, 
IRR+L-NAME, IRR+FM19G11 and IRR+L-NAME+FM19G11, respectively; n.s.). n 
indicates the number of vascular segments used for determinations obtained from, at 
least, three different animals. *** indicates p < 0.001 versus IRR by a two-factors 
ANOVA test. Panel B shows the effects of FM19G11 (1 µM) on cGMP accumulation 
induced by exposure to ACh (10 µM) in aortic tissue from control rats (CR) and IRR 
and the influence of L-NAME (100 µM) on such effects. n indicates the number of 
animals used for determinations. * indicates p < 0.05 versus vehicle, and † p < 0.05 
versus CR by a one-factor ANOVA followed by a Student-Newmann-Keuls test. Panel 
C shows the effects of FM19G11 (1 µM) on aortic content of endothelial NOS (eNOS) 
and its phosphorylated (at Ser177) form (p-eNOS) in CR and IRR. Data are expressed 
as the normalized p-eNOS/eNOS ratio. Numbers of determinations appear in brackets. 
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** indicates p < 0.01 versus vehicle; and †† p < 0.01 versus CR by a one-factor 
ANOVA followed by a Student-Newmann-Keuls test. 
 
Figure 4. Requirement of PI3K/Akt pathway activation in FM19G11-induced 
improvement of endothelial vasodilatation in insulin-resistant rats. Influence of 
inhibition of PI3K with wortmannin (WORT; 500 nM) (A) or LY294002 (LY; 1 µM) 
(B) on the effects of FM19G11 (1 µM) on endothelium-dependent vasodilatation 
elicited by acetylch line (ACh; 10 nM to 10 µM) in aorta from insulin-resistant rats 
(IRR). Data are expressed as mean±SEM of the remaining contraction induced by 
norepinephrine (NE; 1.94±0.14 g, 1.97±0.14 g, 1.91±0.17 g and 2.02±0.16 g for IRR, 
IRR+WORT, IRR+FM19G11 and IRR+WORT+FM19G11 in A; 1.64±0.09 g, 
1.82±0.11 g, 1.66±0.08 g and 1.77±0.14 g for IRR, IRR+LY, IRR+FM19G11 and 
IRR+WORT+FM19G11 in B; n.s. for all comparisons). n indicates the number of 
vascular segments used for determinations that were obtained from, at least, three 
different animals. *** indicates p < 0.001, * p < 0.05 versus IRR, and ††† p < 0.001 
versus IRR+FM19G11 by a two-factors ANOVA test. Panel C shows the effects of 
FM19G11 (1 µM) on aortic content of Akt and its phosphorylated (at Ser473) form (p-
Akt) in IRR and the influence of wortmannin on such effects. Data are expressed as the 
normalized p-Akt/Akt ratio. Numbers of determinations appear in brackets. * indicates 
p < 0.05, ** p < 0.01 versus control, and † p < 0.05 versus FM19G11 by a one-factor 
ANOVA followed by a Student-Newman-Keuls test. 
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Figure 5. FM19G11 increases Akt/eNOS phosphorylation in aortic endothelium 
from insulin-resistant rats. Immunodetection of phosphorylated forms of Akt (Ser473) 
(left panels) and eNOS (Ser1177) (right panels) in aortae from insulin-resistant rats 
(IRR). Panels A and B show immunodetection in aortae from untreated IRR. In C and 
D, aortae from IRR were incubated for 30 min with 1 µM FM19G11. In E and F, aortae 




; i.p.) for 7 days. Red 
fluorescence indicates positive signal. Lower panels show the mean±SEM of the 
percentage of endothelial cells (ECs) positive for p-Akt (G) and p-eNOS (H) in aortae 
from insulin resistant rats after exposure to vehicle or FM19G11 either acute (ex vivo; 




; i.p. for 7 days). 
Numbers of determinations appear in brackets. *** indicates p < 0.001 versus IRR. 
 
Figure 6. Upregulation of HIF-1α by FM19G11 does not contribute to improve 
endothelial vasodilatation in insulin-resistant rats. Panel A shows the effects of 
FM19G11 (1 µM) on protein content of HIF-1α in aortic tissue from control (CR) and 
insulin-resistant rats (IRR). Data are expressed as the normalized HIF-1alpha/ß-actin 
ratio. Numbers of determinations appear in brackets. * indicates p < 0.05, ** p < 0.01 
versus control by a one-factor ANOVA followed by a Student-Newmann-Keuls test. 
Panel B shows the influence of the mammalian target of rapamycin (mTOR) inhibitor, 
rapamycin (RAPA; 20 µM), on the effects of FM19G11 (1 µM) on endothelium-
dependent vasodilatation elicited by acetylcholine (ACh; 10 nM to 10 µM) in aorta from 
insulin-resistant rats (IRR). Data are expressed as mean±SEM of the contraction 
induced by norepinephrine (NE). n indicates the number of vascular segments used for 
determinations which were obtained from, at least, three different animals. *** indicates 
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p < 0.001 versus IRR by a two-factors ANOVA test. Panel C shows a representative 
blotting showing that treatment with RAPA (20 µM) prevents FM19G11-induced HIF-
1α upregulation in aorta of IRR while does not precludes FM19G11-induced Akt 
phosphorylation at Ser473. 
 
Figure 7. FM19G11 recovers endothelium-dependent vasodilatation in human 
penile resistance arteries and corpus cavernsoum. Panel A shows representative 
tracings of the vasodilatation elicited by acetylcholine (ACh; 1 nM to 10 µM) in penile 
resistance arteries from a subject without known erectile dysfunction (No ED) (upper 
tracing) and from a patient with erectile dysfunction (ED) (lower tracings) before (left) 
and after (right) incubation with FM19G11 (1 µM) for 30 min. Other panels show the 
effects of FM19G11 (1 µM) on endothelium-dependent vasodilatation elicited by ACh 
in human penile resistance arteries (HPRA) (B) and corpus cavernosum (HCC) (C) 
from patients with ED. ACh-induced vasodilation in HPRA and HCC from No ED 
subjects is shown for comparison. Data are expressed as mean±SEM of the contraction 
induced by norepinephrine (NE; 6.73±0.68 mN, 6.26±1.73 mN and 6.33±1.51 mN for 
No ED, ED and ED+FM19G11, respectively; n.s. for all comparisons) and 
phenylephrine (PE; 1.20±0.29 g, 0.99±0.22 g and 1.05±0.20 g for No ED, ED and 
ED+FM19G11, respectively; n.s. for all comparisons), respectively. n indicates the 
number of patients from whom the tissues were collected. *** indicates p < 0.001 
versus No ED, ††† p < 0.001 versus ED by a two-factors ANOVA test. 
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Figure 1. Recovery of endothelium-dependent vasodilatation in aorta from insulin-resistant rats by chronic 
FM19G11. Effects of chronic administration of FM19G11 (10 mg•kg-1•day-1; i.p.) for 7 days on 
endothelium-dependent vasodilatation elicited by acetylcholine (ACh; 10 nM to 10 µM) (A) or insulin (0.01 
nM to 1 µM) (B) in aorta from insulin-resistant rats (IRR). Vasodilatations obtained in aorta from control rats 
(CR; non-insulin-resistant) are shown for comparison. Data are expressed as mean±SEM of the contraction 
induced by norepinephrine (NE; 1.80±0.13 g, 1.88±0.16 g, and 1.84±0.1 g for CR, IRR and IRR+FM19G11 
10 mg•kg-1•day-1 in A, n.s.; 1.72±0.17 g, 1.82±0.08 g and 1.86±0.07 g for CR, IRR and IRR+FM19G11 10 
mg•kg-1•day-1 in B, n.s.). n indicates the number of vascular segments used for determinations that were 
obtained from 12 CR, 16 IRR and 6 IRR treated with FM19G11. *** indicates p < 0.001 versus CR and ††† 
p < 0.001 versus IRR by a two-factor ANOVA test.  
254x190mm (72 x 72 DPI)  
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Figure 2. Acute treatment with FM19G11 improves endothelium-dependent vasodilatation in arteries from 
insulin-resistant rats. Panel A displays representative tracings showing the improvement of endothelium-
dependent vasodilatation elicited by acetylcholine (ACh; 10 nM to 10 µM) by FM19G11 (1 µM) (left traces) 
and the lack of contractile tone destabilization by the same treatment (right traces) in aortic segments from 
insulin-resistant rats (IRR). Other panels show the effects of preincubation with FM19G11 (0.3 or 1 µM) on 
vasodilatation elicited by ACh in aorta from control rats (CR) (B), in aorta from IRR (C, D) or in mesenteric 
arteries from IRR (E). Data are expressed as mean±SEM of the contraction induced by norepinephrine (NE; 
1.99±0.08 g vs. 1.96±0.10 g; 1.92±0.12 g vs. 1.86±0.14 g; 1.77±0.08 g vs. 1.82±0.07 g; and  9.28±0.71 
mN vs. 8.48±0.82 mN, control vs. FM19G11 for B, C, D and E, respectively; n.s. for all comparisons). n 
indicates the number of vascular segments used for determinations obtained from, at least, three different 
animals. *** indicates p < 0.001 versus control by a two-factors ANOVA test.  
190x254mm (72 x 72 DPI)  
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Figure 3. Involvement of the NO/cGMP pathway in FM19G11-induced improvement of endothelial 
vasodilatation in insulin-resistant rats. Panel A shows the influence of the NO synthase (NOS) inhibitor, NG-
nitro-L-arginine methyl ester (L-NAME; 100 µM), on the effects of FM19G11 (1 µM) on endothelium-
dependent vasodilatation elicited by acetylcholine (ACh; 10 nM to 10 µM) in aorta from insulin-resistant rats 
(IRR). Data are expressed as mean±SEM of the contraction induced by norepinephrine (NE; 2.10±0.33 g, 
2.45±0.32 g, 2.08±0.23 g and 2.44±0.32 g for IRR, IRR+L-NAME, IRR+FM19G11 and IRR+L-
NAME+FM19G11, respectively; n.s.). n indicates the number of vascular segments used for determinations 
obtained from, at least, three different animals. *** indicates p < 0.001 versus IRR by a two-factors ANOVA 
test. Panel B shows the effects of FM19G11 (1 µM) on cGMP accumulation induced by exposure to ACh (10 
µM) in aortic tissue from control rats (CR) and IRR and the influence of L-NAME (100 µM) on such effects. n 
indicates the number of animals used for determinations. * indicates p < 0.05 versus vehicle, and † p < 
0.05 versus CR by a one-factor ANOVA followed by a Student-Newmann-Keuls test. Panel C shows the 
effects of FM19G11 (1 µM) on aortic content of endothelial NOS (eNOS) and its phosphorylated (at Ser177) 
form (p-eNOS) in CR and IRR. Data are expressed as the normalized p-eNOS/eNOS ratio. Numbers of 
determinations appear in brackets. ** indicates p < 0.01 versus vehicle; and †† p < 0.01 versus CR by a 
one-factor ANOVA followed by a Student-Newmann-Keuls test.  
254x190mm (72 x 72 DPI)  
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Figure 4. Requirement of PI3K/Akt pathway activation in FM19G11-induced improvement of endothelial 
vasodilatation in insulin-resistant rats. Influence of inhibition of PI3K with wortmannin (WORT; 500 nM) (A) 
or LY294002 (LY; 1 µM) (B) on the effects of FM19G11 (1 µM) on endothelium-dependent vasodilatation 
elicited by acetylcholine (ACh; 10 nM to 10 µM) in aorta from insulin-resistant rats (IRR). Data are 
expressed as mean±SEM of the remaining contraction induced by norepinephrine (NE; 1.94±0.14 g, 
1.97±0.14 g, 1.91±0.17 g and 2.02±0.16 g for IRR, IRR+WORT, IRR+FM19G11 and IRR+WORT+FM19G11 
in A; 1.64±0.09 g, 1.82±0.11 g, 1.66±0.08 g and 1.77±0.14 g for IRR, IRR+LY, IRR+FM19G11 and 
IRR+WORT+FM19G11 in B; n.s. for all comparisons). n indicates the number of vascular segments used for 
determinations that were obtained from, at least, three different animals. *** indicates p < 0.001, * p < 
0.05 versus IRR, and ††† p < 0.001 versus IRR+FM19G11 by a two-factors ANOVA test. Panel C shows the 
effects of FM19G11 (1 µM) on aortic content of Akt and its phosphorylated (at Ser473) form (p-Akt) in IRR 
and the influence of wortmannin on such effects. Data are expressed as the normalized p-Akt/Akt ratio. 
Numbers of determinations appear in brackets. * indicates p < 0.05, ** p < 0.01 versus control, and † p < 
0.05 versus FM19G11 by a one-factor ANOVA followed by a Student-Newman-Keuls test.  
254x190mm (72 x 72 DPI)  
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Figure 5. FM19G11 increases Akt/eNOS phosphorylation in aortic endothelium from insulin-resistant rats. 
Immunodetection of phosphorylated forms of Akt (Ser473) (left panels) and eNOS (Ser1177) (right panels) 
in aortae from insulin-resistant rats (IRR). Panels A and B show immunodetection in aortae from untreated 
IRR. In C and D, aortae from IRR were incubated for 30 min with 1 µM FM19G11. In E and F, aortae were 
obtained from IRR treated with FM19G11 (10 mg·kg-1·day-1; i.p.) for 7 days. Red fluorescence indicates 
positive signal. Lower panels show the mean±SEM of the percentage of endothelial cells (ECs) positive for p-
Akt (G) and p-eNOS (H) in aortae from insulin resistant rats after exposure to vehicle or FM19G11 either 
acute (ex vivo; 30 min with 1 µM FM19G11) or chronic (in vivo; 10 mg·kg-1·day-1; i.p. for 7 days). 
Numbers of determinations appear in brackets. *** indicates p < 0.001 versus IRR.  
190x254mm (72 x 72 DPI)  
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Figure 6. Upregulation of HIF-1α by FM19G11 does not contribute to improve endothelial vasodilatation in 
insulin-resistant rats. Panel A shows the effects of FM19G11 (1 µM) on protein content of HIF-1α in aortic 
tissue from control (CR) and insulin-resistant rats (IRR). Data are expressed as the normalized HIF-
1alpha/ß-actin ratio. Numbers of determinations appear in brackets. * indicates p < 0.05, ** p < 0.01 
versus control by a one-factor ANOVA followed by a Student-Newmann-Keuls test. Panel B shows the 
influence of the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (RAPA; 20 µM), on the effects 
of FM19G11 (1 µM) on endothelium-dependent vasodilatation elicited by acetylcholine (ACh; 10 nM to 10 
µM) in aorta from insulin-resistant rats (IRR). Data are expressed as mean±SEM of the contraction induced 
by norepinephrine (NE). n indicates the number of vascular segments used for determinations which were 
obtained from, at least, three different animals. *** indicates p < 0.001 versus IRR by a two-factors ANOVA 
test. Panel C shows a representative blotting showing that treatment with RAPA (20 µM) prevents FM19G11-
induced HIF-1α upregulation in aorta of IRR while does not precludes FM19G11-induced Akt phosphorylation 
at Ser473.  
254x190mm (72 x 72 DPI)  
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Figure 7. FM19G11 recovers endothelium-dependent vasodilatation in human penile resistance arteries and 
corpus cavernsoum. Panel A shows representative tracings of the vasodilatation elicited by acetylcholine 
(ACh; 1 nM to 10 µM) in penile resistance arteries from a subject without known erectile dysfunction (No 
ED) (upper tracing) and from a patient with erectile dysfunction (ED) (lower tracings) before (left) and after 
(right) incubation with FM19G11 (1 µM) for 30 min. Other panels show the effects of FM19G11 (1 µM) on 
endothelium-dependent vasodilatation elicited by ACh in human penile resistance arteries (HPRA) (B) and 
corpus cavernosum (HCC) (C) from patients with ED. ACh-induced vasodilation in HPRA and HCC from No 
ED subjects is shown for comparison. Data are expressed as mean±SEM of the contraction induced by 
norepinephrine (NE; 6.73±0.68 mN, 6.26±1.73 mN and 6.33±1.51 mN for No ED, ED and ED+FM19G11, 
respectively; n.s. for all comparisons) and phenylephrine (PE; 1.20±0.29 g, 0.99±0.22 g and 1.05±0.20 g 
for No ED, ED and ED+FM19G11, respectively; n.s. for all comparisons), respectively. n indicates the 
number of patients from whom the tissues were collected. *** indicates p < 0.001 versus No ED, ††† p < 
0.001 versus ED by a two-factors ANOVA test.  
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